ASCO 2015: Does Hepatocellular Carcinoma Differ in People with Hepatitis B and C?

Liver cancer patients with hepatitis B at a large U.S. cancer center appeared to have worse disease status than those with hepatitis C, including larger tumors and more extensive liver involvement, according to research presented at the American Society of Clinical Oncology (ASCO) annual meeting this month in Chicago. Prognosis for the 2 groups was similar, however.

Read more:

EASL 2015: Hepatitis C Treatment Effective for People with Advanced Liver Disease

New direct-acting antiviral regimens are well-tolerated and produce cure rates far exceeding those of interferon-based therapy for people with decompensated cirrhosis.

Sofosbuvir-based Therapy Effective for Hepatitis C Patients with Decompensated Cirrhosis (HCV-TARGET)

Sofosbuvir + Daclatasvir + Ribavirin Cures Advanced Cirrhosis and Liver Transplant Patients (ALLY-1)

Merck Hepatitis C Combination Achieves 90% Cure in Advanced Cirrhosis Patients (C-SALT)

Sofosbuvir/Ledipasvir + Ribavirin Cures Most Hepatitis C Patients with Advanced Liver Disease (SOLAR-2)

5/7/15

DDW 2015/EASL 2015: Statins Associated with Lower Risk of Death and Liver Decompensation

Hepatitis C patients with liver cirrhosis were significantly less likely to progress to decompensated disease and less likely to die if they used statins to control blood cholesterol, according to an analysis of U.S. veterans presented at the Digestive Disease Week meeting this week in Washington, DC, and at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Another recent study found that statins were associated with better response to hepatitis C treatment and lower risk of liver cancer.

Read more:

EASL 2015: Heavy Alcohol Use Is Strongest Predictor of Liver Damage and Death in French Hepatitis C Patients

People with hepatitis C have a much greater risk of liver-related hospitalization or death if they have an alcohol use disorder or another serious comorbidity such as HIV infection, chronic kidney disease, or cancer, according to an analysis of everyone hospitalized in France between 2008 and 2012 presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna. In the absence of these problems, however, people with hepatitis C did not have an increased risk of death compared to the general population.

Read more: